Immunogenicity and tolerability of an inactivated and adjuvanted pandemic H1N1 influenza vaccine, in HIV-1-infected patients

Cécile L. Tremblay, Danielle Rouleau, Claude Fortin, Emil Toma, Mohamed Sylla, Lise Cyr, Serge Cote, Mariana Baz, John Sampalis, Lydie Trautman, Rafick Pierre Sékaly, Guy Boivin

Research output: Contribution to journalArticlepeer-review

30 Scopus citations

Abstract

We evaluated the efficacy and tolerability of a single dose of the split virion AS03-adjuvanted pandemic H1N1 influenza vaccine (A/California/7/2009) in 84 HIV-1 infected individuals. Antibody titers were determined by hemagglutination inhibition assay and by microneutralization. Vaccine was well tolerated. At 21 days post vaccination, 56 (67%) patients had seroconverted. There was no correlation between baseline CD4 cell count (p = 0.539) or HIV viral load (p = 0.381) and immune response. Other vaccine strategies should be evaluated in this HIV population, to improve response rates.

Original languageEnglish (US)
Pages (from-to)1359-1363
Number of pages5
JournalVaccine
Volume29
Issue number7
DOIs
StatePublished - Feb 4 2011
Externally publishedYes

Keywords

  • Antibody response
  • H1N1
  • HIV
  • Hemaglutinin inhibition
  • Immunogenicity
  • Influenza
  • Microneutralization
  • Pandemic
  • Vaccine

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Immunogenicity and tolerability of an inactivated and adjuvanted pandemic H1N1 influenza vaccine, in HIV-1-infected patients'. Together they form a unique fingerprint.

Cite this